QURE: FDA Setback And 2026 Filings Will Shape Huntington’s Gene Therapy Path

The analyst price target for uniQure has been raised from about $39.05 to roughly $52.56. This reflects analysts' view that the planned biologics license application for AMT-130 in Huntington's disease and recent FDA feedback help support stronger long term revenue growth expectations and a higher future P/E multiple.

Analyst Commentary

Recent research on uniQure clusters around the upcoming biologics license application for AMT-130 in Huntington's disease, with most commentary focused on how this regulatory path could influence the stock's risk profile and valuation.

Bullish Takeaways

Bullish analysts highlight the planned AMT-130 BLA filing for accelerated approval as a key milestone that, if accepted, could help reduce regulatory uncertainty around uniQure and support higher valuation multiples.
Feedback that three year Phase 1/2 data may be acceptable as the primary basis for a BLA is seen as a clear framework for what the regulator is looking for, which bullish analysts view as helpful for execution and timelines.
The view that prior regulatory overhang has been reversed is used by bullish analysts to justify higher price targets, framing uniQure as a more de risked story around its lead Huntington's program.
Upgrades in rating accompanied by price target increases, including one move from US$18 to US$61 and another target set at US$50, indicate that some analysts now see the balance of risk and potential reward for uniQure as more favorable than before.

Bearish Takeaways

Some bearish analysts have previously lowered their price targets, indicating concern about execution risks, data durability, or commercial ramp that could limit how much value uniQure ultimately captures from AMT-130.
Target reductions from certain firms suggest ongoing debate about the appropriate P/E or revenue multiple for uniQure given its development stage, regulatory dependence, and need to deliver on future launches.
The fact that at least one price target remains under review, even after positive regulatory feedback, points to lingering caution around how the upcoming data package and BLA outcome might translate into long term growth.
Mixed target moves across the Street, with some raising and others cutting estimates, underline that uniQure still carries meaningful execution and regulatory risk, which could cap valuation if upcoming milestones do not match current expectations.

What’s in the News for uniQure

uniQure reported that the FDA rejected its accelerated approval application for AMT-130 in Huntington’s disease, with the agency recommending a lengthy, sham-controlled Phase III trial instead. This decision was followed by a sharp 37% decline in the share price, according to recent coverage.
Despite reporting a 75% slowing of disease progression at the high AMT-130 dose versus an external control group, and a generally manageable safety profile, the FDA decision has increased uncertainty around uniQure’s timing and route to potential U.S. market entry for Huntington’s, per the same news reports.
Earlier news highlighted that, following a positive Type B meeting, the FDA indicated it would accept three-year data from uniQure’s AMT-130 studies to support a planned Biologics License Application. The company is targeting a U.S. BLA submission in the third quarter of 2026 and a confirmatory study using standard-of-care controls, based on company and FDA meeting updates.
uniQure completed a pre-submission meeting with the U.K. Medicines and Healthcare products Regulatory Agency and plans to submit a Marketing Authorization Application for AMT-130 in the third quarter of 2026, based on three-year Phase I/II data that showed a statistically significant 75% slowing of disease progression at the high dose, according to the company’s regulatory update.
At its 2026 Annual General Meeting, uniQure shareholders approved amendments to the company’s articles of association that align with the Dutch large company regime, increase authorized share capital, and adopt an exclusive U.S. federal court forum for certain legal disputes. The changes were filed in mid June 2026, based on the company’s AGM and corporate governance disclosures.

Valuation Changes for uniQure Stock

Fair Value: Modelled fair value has risen from about $39.05 to roughly $52.56, an increase of around 35%.
Discount Rate: The discount rate has edged slightly lower from 7.42% to about 7.40%.
Revenue Growth: Assumed long term revenue growth has moved higher from roughly 122.84% to about 137.44%.
Net Profit Margin: Net profit margin assumptions are largely unchanged, moving marginally from about 19.04% to roughly 18.98%.
Future P/E: The future P/E multiple in the model has increased from roughly 97.78x to about 109.07x.

0 views

Key Takeaways

Accelerated approval of AMT-130 for Huntington's could significantly boost future revenues as it would be a pioneering treatment.
Strategic financial actions and strong cash reserves provide resilience and flexibility, supporting pipeline advancement and likely improving margins.
Reliance on AMT-130’s success and regulatory outcomes, amid revenue challenges and manufacturing changes, heightens exposure to product development and supply chain risks.

Catalysts

About uniQure

Develops treatments for patients suffering from rare and other devastating diseases in the United States.What are the underlying business or industry changes driving this perspective?

The potential accelerated approval for AMT-130 in treating Huntington's disease could significantly boost future revenues as it would be one of the first disease-modifying treatments available for this condition.
Expansion of the clinical pipeline with new studies in refractory temporal lobe epilepsy, Fabry disease, and SOD1-ALS could lead to additional revenue streams if these treatments are successful and commercialized.
The company’s strategic financial moves, including reducing cash burn and strengthening the balance sheet through a targeted offering, provide financial resilience and flexibility to support pipeline advancement and potentially improve net margins.
With strong cash reserves of over $400 million, uniQure is well-positioned to fund operations through the launch of AMT-130 and support other key data readouts, likely impacting earnings positively.
Impressive clinical results and newly granted breakthrough therapy designation for AMT-130 might enhance investor confidence, potentially driving stock value through anticipated increases in revenue and investor sentiment.

uniQure Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming uniQure's revenue will grow by 137.4% annually over the next 3 years.
Analysts are not forecasting that uniQure will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate uniQure's profit margin will increase from -1154.4% to the average US Biotechs industry of 19.0% in 3 years.
If uniQure's profit margin were to converge on the industry average, you could expect earnings to reach $46.0 million (and earnings per share of $0.6) by about June 2029, up from -$208.9 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $113.6 million in earnings, and the most bearish expecting $-290.2 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 109.4x on those 2029 earnings, up from -14.5x today. This future PE is greater than the current PE for the US Biotechs industry at 16.4x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.4%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The company's reliance on successful regulatory outcomes, specifically the BLA submission for AMT-130, coupled with uncertainties about FDA interactions and changes in FDA leadership, poses a risk that could impact revenue and projected market entry timelines.
The decrease in revenue from $8.5 million in Q1 2024 to $1.6 million in Q1 2025 highlights challenges in sustaining revenue streams, which may affect the company's short-term financial health.
The divestiture of the GMP manufacturing facility and reliance on external entities for manufacturing could impact cost efficiencies or lead to potential supply chain disruptions, affecting net margins.
The presence of serious adverse events related to immunosuppression in clinical trials indicates risks that may require additional resources to address or delay product timelines, potentially impacting future earnings.
The company's strong dependency on the success of AMT-130 and limited diversification of revenue-generating products increase their exposure to product development risks which might impact future revenue if any set targets are not met.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $52.56 for uniQure based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $93.29, and the most bearish reporting a price target of just $24.54.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $242.2 million, earnings will come to $46.0 million, and it would be trading on a PE ratio of 109.4x, assuming you use a discount rate of 7.4%.
Given the current share price of $48.16, the analyst price target of $52.56 is 8.4% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on uniQure?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

QURE: Pivotal Three-Year Huntington’s Data Will Drive Approval and Market Uptake